Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed Phase 2 Interventional Results available

Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

NCT01234402
View directory record Official record
Conditions
Breast Cancer
Interventions
Ramucirumab DP, IMC-18F1, Capecitabine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Oct 24, 2026, 2:35 PM EDT
Active, not recruiting Phase 1 Interventional

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases

NCT03696030
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer
Interventions
Chimeric Antigen Receptor T-Cell Therapy
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women

NCT05275361
View directory record Official record
Conditions
Breast Cancer
Interventions
Social Contact Reminder
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Oct 24, 2026, 2:35 PM EDT
Completed No phase listed Observational

OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer

NCT00900302
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Pre-Operative Radiation and Veliparib for Breast Cancer

NCT01618357
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation, Lumpectomy/Mastectomy, Veliparib
Radiation · Procedure · Drug
Lead sponsor
Richard Zellars
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
6
States / cities
Avon, Indiana • Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 24, 2026, 2:35 PM EDT
Recruiting Phase 4 Interventional

Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks

NCT06574022
View directory record Official record
Conditions
Mastectomy; Lymphedema, Breast Cancer
Interventions
Bupivacain, Exparel, Intraoperative Pecs II block (IOB) & superior AT (EX or BP), Preoperative Pecs II block (POB) & superior AT (EX or BP)
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Intraoperative Radiotherapy for Early Stage Breast Cancer

NCT01189851
View directory record Official record
Conditions
Breast Cancer
Interventions
Intraoperative Radiotherapy
Device
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
48 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Multipeptide Vaccine for Advanced Breast Cancer

NCT00573495
View directory record Official record
Conditions
Breast Neoplasm, Breast Cancer, Cancer of the Breast, Carcinoma, Ductal
Interventions
hTERT/Survivin Multi-Peptide Vaccine
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 24, 2026, 2:35 PM EDT
Recruiting Not applicable Interventional

SAVE Trial: SAfe Opioid Use Video Education

NCT07044583
View directory record Official record
Conditions
Breast Reconstruction, Breast Cancer
Interventions
Opioid Educational Video
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 24, 2026, 2:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

NCT02650401
View directory record Official record
Conditions
Solid Tumors, CNS Tumors
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
0 Years to 18 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 2:35 PM EDT
Recruiting Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

NCT06515470
View directory record Official record
Conditions
Breast Cancer
Interventions
BTX-9341, Fulvestrant
Drug
Lead sponsor
Biotheryx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Rochester, Minnesota • Omaha, Nebraska • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 24, 2026, 2:35 PM EDT
Terminated Not applicable Interventional

Sensory Restoration After DIEP Flap Neurotization

NCT04533373
View directory record Official record
Conditions
Breast Cancer, Breast Reconstruction, Sensory Restoration
Interventions
DIEP Flap Neurotization
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Female only
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 24, 2026, 2:35 PM EDT
Recruiting Phase 2 Interventional

TRUDI: TDXD+Durva in HER2+/Low IBC

NCT05795101
View directory record Official record
Conditions
Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
Interventions
Trastuzumab deruxtecan, Durvalumab
Drug
Lead sponsor
Filipa Lynce, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Feasibility Study of the Addition of a Personal Trainer to the Post-Treatment Regimen of Breast Cancer Survivors

NCT02770781
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise regimen
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Preoperative Herceptin and Navelbine for Breast Cancer

NCT00148681
View directory record Official record
Conditions
Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Herceptin, Navelbine, Doxorubicin, Cyclophosphamide, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

NCT00001302
View directory record Official record
Conditions
Breast Cancer, Kidney Neoplasm, Lymphoma, Neoplasm Metastasis, Ovarian Cancer
Interventions
PSC 833
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

NCT02273973
View directory record Official record
Conditions
Breast Cancer
Interventions
Letrozole, Placebo, Taselisib
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
8
States / cities
Santa Ana, California • Boston, Massachusetts • Basking Ridge, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

NCT00270894
View directory record Official record
Conditions
Breast Neoplasm
Interventions
epirubicin, cyclophosphamide, docetaxel, trastuzumab
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity

NCT05051631
View directory record Official record
Conditions
Breast Cancer
Interventions
Intervention plus 12 months maintenance, Intervention plus 10 months maintenance, Intervention plus 8 months maintenance, Intervention plus 6 months maintenance, Intervention plus 4 months maintenance
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
25 Years to 49 Years · Female only
Enrollment
1,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

A Mind-Body Intervention for Hot Flash Management

NCT03572153
View directory record Official record
Conditions
Hot Flashes, Postmenopausal Symptoms, Breast Cancer
Interventions
Self-Administered Hypnosis, Self-Administered White Noise Hypnosis
Behavioral
Lead sponsor
Baylor University
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Waco, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 24, 2026, 2:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Tumor-Derived FGF19

NCT06068257
View directory record Official record
Conditions
Colorectal Cancer, Breast Cancer, Healthy
Interventions
Not listed
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Infrared Imaging for Breast Cancer Modeling

NCT03990012
View directory record Official record
Conditions
Breast Cancer
Interventions
IR Imaging, 3D Scanning
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 24, 2026, 2:35 PM EDT
Completed No phase listed Observational

Evaluation of SOMAVAC 100 Sustained Vacuum System

NCT04845256
View directory record Official record
Conditions
Breast Cancer
Interventions
SOMAVAC 100 Sustained Vacuum System
Device
Lead sponsor
University of Tennessee
Other
Eligibility
21 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 24, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

Smartphone Technology to Alleviate Malignant Pain (STAMP)

NCT03717402
View directory record Official record
Conditions
Cancer, Pain Management, Opioid Use
Interventions
Intervention Participants
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 24, 2026, 2:35 PM EDT